When we wrote (September 21) that conflicts of interest among journal editors are not being addressed, we were neglecting the case of Charles Nemeroff, the editor-in-chief of Neuropsychopharmacology. Nemeroff is the chairman of the department of psychiatry and behavioral sciences at Emory University medical school in Atlanta.
As the Wall Street Journal reported earlier this summer, a favorable review by Nemeroff of a device to treat depression, published in Neuropsychopharmacology, failed to disclose his ties to Cyberonics, the manufacturer of the device. The fact that his six academic coauthors had ties to Cyberonics, as the medical journal later revealed, was also left unmentioned; the eighth coauthor works at the company.
